Cogent Biosciences, Inc. (COGT)
30.21
-0.17
(-0.56%)
USD |
NASDAQ |
Oct 07, 14:18
Cogent Biosciences Net Income (Quarterly) : -96.40M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -96.40M |
| March 31, 2026 | -97.35M |
| December 31, 2025 | -102.49M |
| September 30, 2025 | -80.93M |
| June 30, 2025 | -73.53M |
| March 31, 2025 | -71.99M |
| December 31, 2024 | -67.93M |
| September 30, 2024 | -70.63M |
| June 30, 2024 | -58.95M |
| March 31, 2024 | -58.35M |
| December 31, 2023 | -54.36M |
| September 30, 2023 | -55.38M |
| June 30, 2023 | -44.08M |
| March 31, 2023 | -38.59M |
| December 31, 2022 | -39.62M |
| September 30, 2022 | -35.06M |
| June 30, 2022 | -34.93M |
| March 31, 2022 | -30.63M |
| Date | Value |
|---|---|
| December 31, 2021 | -24.91M |
| September 30, 2021 | -19.08M |
| June 30, 2021 | -16.55M |
| March 31, 2021 | -11.73M |
| December 31, 2020 | -11.34M |
| September 30, 2020 | -49.98M |
| June 30, 2020 | -7.393M |
| March 31, 2020 | -6.094M |
| December 31, 2019 | 2.297M |
| September 30, 2019 | -11.92M |
| June 30, 2019 | -10.52M |
| March 31, 2019 | -11.69M |
| December 31, 2018 | -8.606M |
| September 30, 2018 | -10.17M |
| June 30, 2018 | -9.023M |
| March 31, 2018 | -6.751M |
| December 31, 2017 | -6.706M |
| September 30, 2017 | -7.016M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Moderna, Inc. | -782.00M |
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 96.40M |
| EPS Diluted (Quarterly) | -0.5636 |
| Enterprise Value | 4.731B |
| Earnings Yield | -8.09% |
| Normalized Earnings Yield | -7.981 |